128 related articles for article (PubMed ID: 6209145)
1. Serum tumour marker regression rate following chemotherapy for malignant teratoma.
Horwich A; Peckham MJ
Eur J Cancer Clin Oncol; 1984 Dec; 20(12):1463-70. PubMed ID: 6209145
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
Stevens MJ; Norman AR; Dearnaley DP; Horwich A
J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
[TBL] [Abstract][Full Text] [Related]
3. Prognosis following chemotherapy for metastatic malignant teratoma.
Horwich A; Easton D; Husband J; Nicholas D; Peckham MJ
Br J Urol; 1987 Jun; 59(6):578-83. PubMed ID: 2446691
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum tumor markers in patients with testicular cancer after induction chemotherapy due to a reservoir of markers in cystic differentiated mature teratoma.
van der Gaast A; Hoekstra JW; Croles JJ; Splinter TA
J Urol; 1991 Apr; 145(4):829-31. PubMed ID: 1706441
[TBL] [Abstract][Full Text] [Related]
5. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
de Wit R; Sylvester R; Tsitsa C; de Mulder PH; Sleyfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Vermeylen K; Stoter G
Br J Cancer; 1997; 75(3):432-5. PubMed ID: 9020492
[TBL] [Abstract][Full Text] [Related]
6. Transient rise in tumor marker after initial adjuvant chemotherapy for testicular cancer.
Wolf DJ; Williams JJ
Urology; 1982 Jul; 20(1):50-2. PubMed ID: 6180542
[No Abstract] [Full Text] [Related]
7. The value of AFP and HCG half lives in predicting the efficacy of combination chemotherapy in patients with non-seminomatous germ cell tumors of the testis.
Willemse PH; Sleijfer DT; Schraffordt Koops H; De Bruijn HW; Oosterhuis JW; Brouwers TM; Ockhuizen T; Marrink J
Oncodev Biol Med; 1981; 2(1-2):129-34. PubMed ID: 6170953
[TBL] [Abstract][Full Text] [Related]
8. Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours.
Horwich A; Brada M; Nicholls J; Jay G; Hendry WF; Dearnaley D; Peckham MJ
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):177-84. PubMed ID: 2467806
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of patients in whom germ cell tumour masses enlarged on chemotherapy while their serum tumour markers decreased.
Tonkin KS; Rustin GJ; Wignall B; Paradinas F; Bennett M
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1739-43. PubMed ID: 2483686
[TBL] [Abstract][Full Text] [Related]
10. The UK Children's Cancer Study Group: testicular malignant germ cell tumours 1979-1988.
Huddart SN; Mann JR; Gornall P; Pearson D; Barrett A; Raafat F; Barnes JM; Wallendsus KR
J Pediatr Surg; 1990 Apr; 25(4):406-10. PubMed ID: 1691781
[TBL] [Abstract][Full Text] [Related]
11. Benign intracranial hypertension during chemotherapy for testicular teratoma.
Marsh LF; Morgan DA; Jefferson D
Br J Radiol; 1988 Aug; 61(728):692. PubMed ID: 2458158
[No Abstract] [Full Text] [Related]
12. Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis.
Horwich A; Peckham MJ
Cancer Treat Rep; 1986 Nov; 70(11):1329-31. PubMed ID: 2429765
[TBL] [Abstract][Full Text] [Related]
13. Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors.
Vogelzang NJ; Lange PH; Goldman A; Vessela RH; Fraley EE; Kennedy BJ
Cancer Res; 1982 Nov; 42(11):4855-61. PubMed ID: 6181870
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin combination chemotherapy for advanced germ-cell testicular tumours.
Taylor RE; Duncan W; Davey P; Munro AJ; Cornbleet MA
Br J Urol; 1985 Oct; 57(5):567-73. PubMed ID: 2415203
[TBL] [Abstract][Full Text] [Related]
15. [Limitations of tumor marker surveillance after chemotherapy in advanced non-seminomatous testicular tumors].
Behrendt H; Ringert RH; Pfeiffer R; Homann W; Hartung R
Urol Int; 1983; 38(5):307-9. PubMed ID: 6195793
[TBL] [Abstract][Full Text] [Related]
16. Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT).
de Bono JS; Paul J; Simpson A; Anthoney A; Kirk D; Underwood M; Graham J; Kaye SB
Br J Cancer; 2000 Aug; 83(4):426-30. PubMed ID: 10945485
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in metastatic nonseminomatous germ cell tumours.
Hanson PR; Belitsky P; Millard OH; Lannon SG
Can J Surg; 1993 Dec; 36(6):537-40. PubMed ID: 7504978
[TBL] [Abstract][Full Text] [Related]
18. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer.
Christensen TB; Engbaek F; Marqversen J; Nielsen SI; Kamby C; von der Maase H
Br J Cancer; 1999 Jul; 80(10):1577-81. PubMed ID: 10408402
[TBL] [Abstract][Full Text] [Related]
19. [Case report of a non-seminomatous testicular neoplasm indicating marked efficacy of a combination chemotherapy of VBL, ACTD, BLM, CDDP and EX (VAB-4 combination therapy)].
Hayashi M; Ebihara K; Urano E
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2775-7. PubMed ID: 6210063
[TBL] [Abstract][Full Text] [Related]
20. Pre-, per- and post-chemotherapy tumour markers in very advanced testicular cancer.
Fossa SD; Paus E
Prog Clin Biol Res; 1985; 203():121. PubMed ID: 2421325
[No Abstract] [Full Text] [Related]
[Next] [New Search]
